- Report
- August 2025
- 191 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- April 2025
- 200 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Report
- August 2025
- 193 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 180 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- March 2025
Global
From €4307EUR$4,900USD£3,725GBP
- Report
- April 2025
- 130 Pages
Global
From €4307EUR$4,900USD£3,725GBP
- Report
- February 2025
- 287 Pages
Global
From €4834EUR$5,500USD£4,182GBP
- Report
- May 2025
- 144 Pages
Global
From €2636EUR$2,999USD£2,280GBP
- Report
- November 2024
- 120 Pages
Global
From €5230EUR$5,950USD£4,524GBP
- Report
- December 2024
- 200 Pages
Global
From €5230EUR$5,950USD£4,524GBP
- Report
- February 2025
- 135 Pages
Global
From €2189EUR$2,490USD£1,893GBP
- Report
- April 2025
- 200 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Report
- January 2025
- 175 Pages
Global
From €3947EUR$4,490USD£3,414GBP
- Report
- August 2025
- 194 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 194 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 186 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 185 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 186 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 199 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP
- Report
- August 2025
- 195 Pages
Global
From €3116EUR$3,545USD£2,695GBP
€3462EUR$3,939USD£2,995GBP

The Cell Free DNA (cfDNA) market is a subset of the genomics industry that focuses on the analysis of circulating DNA fragments in the bloodstream. It is used to detect genetic abnormalities, such as chromosomal aneuploidy, and to monitor cancer progression. cfDNA testing is also used to detect fetal genetic abnormalities during pregnancy.
The cfDNA market is expected to grow rapidly in the coming years, driven by increasing demand for non-invasive prenatal testing and the development of new technologies. The market is also expected to benefit from the increasing availability of cfDNA testing kits and the growing awareness of its potential applications.
Notable companies in the cfDNA market include Illumina, Thermo Fisher Scientific, Qiagen, Natera, and Guardant Health. Show Less Read more